Paradoxical and Bimodal Immune-mediated Dermatological Side Effects of TNF-α Inhibitors: A Comprehensive Review

Overview

Journal Skin Res Technol

Specialty Biomedical Engineering

Date 2024 May 3

PMID 38700458

Authors

Elham Behrangi

Farzan Moodi

Alireza Jafarzadeh

Azadeh Goodarzi

Affiliations

Soon will be listed here.

Abstract

Introduction: Due to the increasing prevalence of immune-mediated diseases such as psoriasis, lichen planus, rheumatoid arthritis and inflammatory bowel disease, dermatologists have turned to new biologic drugs known as DMARDs (disease-modifying anti-rheumatic drugs) in recent years.

Areas Covered: In this study, we evaluate the immune-mediated dermatological side effects of DMARDS by reviewing and analyzing previous peer-reviewed research on the effects of TNF-α inhibitors in the treatment of skin diseases, as well as adverse effects of these drugs and some of the main causes of these effects.

Expert Opinion: DMARDs are very effective in improving control of the above diseases. TNF-α inhibitors are an important group of DMARDs that are widely used. The paradoxical adverse events (PAEs) associated with the use of TNF-α inhibitors are divided into three categories: true paradoxical, borderline paradoxical, and non-paradoxical. True PAEs include conditions for which TNF-α inhibitors are approved for treatment. Borderline PAEs are considered to occur with this class of drugs for which there is no definite approval but for which there is sufficient evidence. Although these events are rare, early recognition of the accused drug and appropriate decision-making may prevent progression of complications and irreversible side effects.

Citing Articles

Emerging treatments for dermatologic diseases in infants, children, and adolescents: a systematic review of clinical trials on biologics and small molecule inhibitors.

Jafarzadeh A, Behrangi E, Khosravi M, Falakeh S, Amiri J, Goodarzi A Inflammopharmacology. 2025; .

PMID: 40042725 DOI: 10.1007/s10787-025-01675-4.

(L.) Delile Is a Promising Marine Source Able to Alleviate Imiquimod-Induced Psoriatic Skin Inflammation.

Micheli L, Vasarri M, DeglInnocenti D, Di Cesare Mannelli L, Ghelardini C, Emiliano A Mar Drugs. 2024; 22(7).

PMID: 39057409 PMC: 11277884. DOI: 10.3390/md22070300.

Paradoxical and bimodal immune-mediated dermatological side effects of TNF-α inhibitors: A comprehensive review.

Behrangi E, Moodi F, Jafarzadeh A, Goodarzi A Skin Res Technol. 2024; 30(5):e13718.

PMID: 38700458 PMC: 11067872. DOI: 10.1111/srt.13718.

References

Zhang S, Tang S, Li S, Pan Y, Ding Y . Biologic TNF-alpha inhibitors in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a systemic review. J Dermatolog Treat. 2019; 31(1):66-73. DOI: 10.1080/09546634.2019.1577548. View

Oliveira S, Costa Vasconcelos A, Magalhaes E, Correa F, Rodrigues C . Clinical, Histopathological and Outcome Analysis of Five Patients With Lichenoid Eruption Following Anti-Tumor Necrosis Factor-Alpha Therapy for Ankylosing Spondylitis: Report of One Case and Review of the Literature. Cureus. 2020; 12(9):e10598. PMC: 7581215. DOI: 10.7759/cureus.10598. View

Ramos-Casals M, Brito-Zeron P, Munoz S, Soria N, Galiana D, Bertolaccini L . Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore). 2007; 86(4):242-251. DOI: 10.1097/MD.0b013e3181441a68. View

Melikoglu M, Fresko I, Mat C, Ozyazgan Y, Gogus F, Yurdakul S . Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study. J Rheumatol. 2005; 32(1):98-105. View

Li S, Perez-Chada L, Merola J . TNF Inhibitor-Induced Psoriasis: Proposed Algorithm for Treatment and Management. J Psoriasis Psoriatic Arthritis. 2019; 4(2):70-80. PMC: 6513344. DOI: 10.1177/2475530318810851. View

Kowalzick L, Bertolini J, Baumann C, Walther B, Truhm B, Eickenscheidt L . Paradoxical reaction to etanercept: development of pyoderma gangraenosum during therapy of psoriasis arthritis. J Dtsch Dermatol Ges. 2013; 11(5):447-9. DOI: 10.1111/ddg.12032. View

Ahdout J, Haley J, Chiu M . Erythema multiforme during anti-tumor necrosis factor treatment for plaque psoriasis. J Am Acad Dermatol. 2009; 62(5):874-9. DOI: 10.1016/j.jaad.2009.04.048. View

Ogrum A, Takci Z, Seckin H, Cetin E . Treatment resistant impetigo herpetiformis treated with infliximab. Dermatol Ther. 2019; 32(2):e12839. DOI: 10.1111/dth.12839. View

Tan C, Novoa R, Chen J . Erythematous Plaques on the Buttock. JAMA. 2016; 315(1):79-80. DOI: 10.1001/jama.2015.13562. View

10.

Kennedy J, Devillez R, Henning J . Recalcitrant cicatricial pemphigoid treated with the anti-TNF-alpha agent etanercept. J Drugs Dermatol. 2010; 9(1):68-70. View

11.

Behrangi E, Moodi F, Jafarzadeh A, Goodarzi A . Paradoxical and bimodal immune-mediated dermatological side effects of TNF-α inhibitors: A comprehensive review. Skin Res Technol. 2024; 30(5):e13718. PMC: 11067872. DOI: 10.1111/srt.13718. View

12.

Wilmer E, Becker N, Chen A, Kroumpouzos G . Etanercept-induced generalization of chronic, localized, anogenital bullous pemphigoid in a psoriatic patient. JAAD Case Rep. 2016; 2(1):25-7. PMC: 4809470. DOI: 10.1016/j.jdcr.2015.12.006. View

13.

Puig L . Paradoxical Reactions: Anti-Tumor Necrosis Factor Alpha Agents, Ustekinumab, Secukinumab, Ixekizumab, and Others. Curr Probl Dermatol. 2017; 53:49-63. DOI: 10.1159/000479475. View

14.

Sokumbi O, Wetter D, Makol A, Warrington K . Vasculitis associated with tumor necrosis factor-α inhibitors. Mayo Clin Proc. 2012; 87(8):739-45. PMC: 3538488. DOI: 10.1016/j.mayocp.2012.04.011. View

15.

Vaglio A, Grayson P, Fenaroli P, Gianfreda D, Boccaletti V, Ghiggeri G . Drug-induced lupus: Traditional and new concepts. Autoimmun Rev. 2018; 17(9):912-918. DOI: 10.1016/j.autrev.2018.03.016. View

16.

Tugnet N, Youssef A, Whallett A . Wells' syndrome (eosinophilic cellulitis) secondary to infliximab. Rheumatology (Oxford). 2011; 51(1):195-6. DOI: 10.1093/rheumatology/ker322. View

17.

Kikuchi N, Hiraiwa T, Ohashi T, Hanami Y, Satoh M, Takenoshita H . Pyoderma gangrenosum possibly triggered by adalimumab. Eur J Dermatol. 2012; 22(6):804-5. DOI: 10.1684/ejd.2012.1849. View

18.

Segaert S, Hermans C . Clinical Signs, Pathophysiology and Management of Cutaneous Side Effects of Anti-Tumor Necrosis Factor Agents. Am J Clin Dermatol. 2017; 18(6):771-787. DOI: 10.1007/s40257-017-0296-7. View

19.

Mounach A, Rezqi A, Nouijai A, Ghozlani I, Achemlal L, El Maghraoui A . Stevens-Johnson syndrome complicating adalimumab therapy in rheumatoid arthritis disease. Rheumatol Int. 2011; 33(5):1351-3. DOI: 10.1007/s00296-011-2212-4. View

20.

Salama M, Lawrance I . Stevens-Johnson syndrome complicating adalimumab therapy in Crohn's disease. World J Gastroenterol. 2009; 15(35):4449-52. PMC: 2747069. DOI: 10.3748/wjg.15.4449. View